Top

Published in:

01-08-2023 | Hyperthyroidism | Review

Combined paclitaxel or nab-PTX and ICIs reduces risk of irAEs

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Treatment with paclitaxel (PTX) or nanoparticle-bound paclitaxel (nab-PTX) in combination with immune checkpoint inhibitors (ICIs) can reduce the risk of immune-related adverse events (irAEs) in patients with cancer compared with ICI alone, according to findings of a systematic review and network meta-analysis published in Frontiers in Immunology. …

Hao W, et al. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis Frontiers in Immunology : 14 Jul 2023. Available from: URL: https://doi.org/10.3389/fimmu.2023.1175809

Title: Combined paclitaxel or nab-PTX and ICIs reduces risk of irAEs
Publication date: 01-08-2023
Publisher: Springer International Publishing
Keywords: Hyperthyroidism
Checkpoint Inhibitors
Hypothyroidism
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-44171-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Combined paclitaxel or nab-PTX and ICIs reduces risk of irAEs

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

AZD 1222

Fentanyl/naldemedine

Infliximab

Cabozantinib

Doxazosin/levodopa/carbidopa/paroxetine

Levodopa